- Key considerations for planning and determining the suitability of DCTs
- Reviewing how DCTs can enhance trial reach and significantly boost patient recruitment
- Sharing practical insights and lessons learned from implementing DCTs
Archives: Agenda
Exploring GCC Clinical research Landscape
- Infrastructure Strengths of the UAE & GCC for Clinical Research
- UAE’s Precision Medicine and Genomics Ecosystem: A Global Benchmark
- Why the GCC is Emerging as the Next Global Hub for Clinical Trials
Empowering Biotechs in Asia: The Strategic Role of CROs for Korean and Regional Sponsors
· Expansion Support: CROs guide Korean biotechs through regulations, operations, and global site access to move beyond domestic trials.
· Asia Hub Model: With hubs in Korea and Taiwan, CROs like Avance Clinical offer turnkey infrastructure — entities, vendors, and site partnerships.
· From Phase I to MRCTs: Linking Australia’s fast Phase I ecosystem with Asia’s Phase II/III scale accelerates global development.
Bridging Borders and Regulations: QPS Perspectives on US FDA and APAC Alignment
- Regulatory landscape US: Pre-IND and IND
- Bridging APAC With US
- Current US administration / FDA – What are we seeing at QPS?
Developing a Clinical Oversight Strategy Using Big Data and BI Tools
| · Enhancing oversight of CROs, vendors, and trial sites through centralized data insights
· Utilizing Business Intelligence (BI) tools to visualize trial health in real time · Case examples of effective use of BI tools in optimizing clinical timelines, cost, and compliance |
Reserved for Nucleus Network
Patient Access in Clinical Trials : Global Trends and What It Means to South Korea
|
Lunch and networking
Afternoon refreshments and networking
From Hurdles to Insights: Navigating Early-Stage Clinical Trials
• Addressing common scientific and operational challenges in early phase trials
• Evaluating the necessity of placebo groups in Phase 1 trials
• Managing protocol designs incorporating biomarkers and adaptive trial elements